Cardiol Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Cardiol Therapeutics Inc CRDL.TO reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended June 30, identical to the same quarter last year. The mean expectation of three analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -13 cents to -12 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Cardiol Therapeutics Inc's reported EPS for the quarter was a loss of 10 cents​.

• The company reported a quarterly loss of C$8.35 million.

• Cardiol Therapeutics Inc shares had fallen by 1.5% this quarter and gained 4.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Cardiol Therapeutics Inc is $9.00, about 85.1% above its last closing price of $1.34

This summary was machine generated from LSEG data August 15 at 04:45 p.m. UTC. ​All figures in Canadian dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)